Skip to main content

INSIGHT-HD: Investigating the Genetics of Hematologic Diseases


Hematological Disorders

Sickle Cell Disease

Diseases Treated:

Non-malignant blood diseases (non-therapeutic)

Eligibility Overview:

  • Receiving therapy or a consultation for a non-malignant blood disorder
  • Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
  1. Brief Summary

    The purpose of this study is to collect and store blood and bone marrow samples and health information from patients with non-malignant hematologic diseases and their biological relatives in order to conduct current and future research on these diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Researchers will use genetic and/or genomic research to study the samples.

    Primary Objective 

    • To establish a DNA repository to facilitate family-based studies of biologically related individuals

    Secondary Objectives

    • Identify novel mutations that associate with non-malignant blood diseases.
    • Evaluate genetic variants associated with phenotypic variability, treatment outcomes and toxicities for individuals with defined monogenic non-malignant blood diseases. 
    • Explore the feasibility of using patient-derived hematopoietic progenitors and induced pluripotent stem (iPS) cells to develop disease-specific models of hematopoietic differentiation.


    • Individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and  
    • Affected and unaffected biological family members of those individuals who are willing to provide clinical data and undergo genetic testing
  2. About this clinical trial

    This study is for patients who have a blood disease that is not cancerous and for related family members. Non-cancerous blood diseases, also called hematological disorders, include a wide range of conditions. The most well-known examples are sickle cell anemia and bone marrow failure syndromes. Bone marrow failure syndromes may include: 

    • Congenital neutropenia
    • Dyskeratosis congenital (DKC), also known as Zinsser-Cole-Engleman syndrome
    • Diamond-Blackfan anemia (DBA)
    • Fanconi anemia
    • Congenital thrombocytopenia

    Researchers know that genes play a role in transmitting blood diseases in families, but they need to learn more about this process. Learning how genes cause and influence blood diseases can help them better predict and treat these diseases. They also want to study families to learn more about how blood diseases are inherited. 

    Genetic and genomic research involves molecules such as DNA. DNA is the “instruction book” for the cells that make up our bodies. Our genes are made up of DNA, and a genome is a complete set of DNA.  Each person’s DNA is unique, and changes in DNA can lead to developing or having a blood disorder. By studying the genomes in individuals with blood diseases and their family members, St. Jude researchers hope to learn about how diseases develop and respond to treatment. Eventually, this research may lead to new and better ways to diagnose and treat these diseases.

    Purpose of this clinical trial

    The main goal of this trial is to collect DNA from individuals with non-cancerous blood diseases and their family members. Researchers will use the DNA to study how genes cause and influence these diseases. All research data will be confidential.

    Study protocol

    Participants will provide samples of blood and bone marrow. The blood and bone marrow samples of study participants may not be studied right away. Researchers will store the samples and evaluate them at the best time.

    Eligibility overview

    • Male or female of any age receiving therapy or a consultation for a non-malignant blood disorder, and
    • Biological relatives (with or without a non-malignant blood disorder) who agree to undergo genetic testing
  3. INSIGHT-HD Quick View
    Sponsor St. Jude Children's Research Hospital Identifier NCT02720679
    Trial Start Date March 2016
    Estimated Enrollment 1,716
    Study Type Non-therapeutic/Observational
    Study Phase Phase I
    Conditions Non-Malignant Hematological Disorders
    Ages Any
    Principal Investigator Marcin Wlodarski, MD, PhD
    Study Site St. Jude Children's Research Hospital
    For a consultation or to discuss INSIGHT-HD St. Jude Physician/Patient Referral Office

St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105  USA
Voice: 1-888-226-4343 or 901-595-4055
24-Hour Emergency Access Pager: 1-800-349-4334

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.